The Female Health Company / Veru Healthcare Announces Successful Stage 1 of the Clinical Trial to Evaluate Bioequivalence Between Tamsulosin DRS and FLOMAX®
FEMALE HEALTH (FHCO)
US:NASDAQ Investor Relations:
verupharma.com/investors
Company Research
Source: GlobeNewswire
--Stage 1 of Clinical Trial Completed; A Tamsulosin DRS Formulation is Selected That Demonstrates Profile Similar to FLOMAX® and May Provide Other Potential Advantages, Including Ease-of-Use and Safety Benefits; New Tamsulosin DRS Formulation Advances to Stage 2; Planned NDA Filing Under the 505(b)(2) Regulatory Pathway On Track; Approval Expected in Second Half of 2018-- MIAMI, April 12, 2017 (GLOBE NEWSWIRE) -- The Female Health Company / Veru Healthcare (NASDAQ:FHCO) today announced the successful Stage 1 of a bioequivalence (BE) clinical trial which was designed to select the optimal formulation of its proprietary Tamsulosin Delayed Release Sachet (DRS) product. Tamsulosin DRS is a new, slow release oral powder formulation that addresses the large patient population of men with benign prostatic hyperplasia (BPH) who have difficulty swallowing ta
Show less
Read more
Impact Snapshot
Event Time:
FHCO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FHCO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FHCO alerts
High impacting FEMALE HEALTH news events
Weekly update
A roundup of the hottest topics